Biomarin Pharmaceutical Inc
NASDAQ: BMRN
$89.49
+$0.86 (+1.0%)
Closing price April 22, 2024
BioMarin Pharmaceutical stock was crushed on Wednesday after an FDA response regarding its valoctocogene roxaparvovec gene therapy for severe hemophilia A.
Published:
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
Published:
Wednesday's top analyst upgrades and downgrades Apple, Boeing, Chevron, Chewy, Cisco Systems, Cree, eBay, Etsy, GameStop, Groupon, Micron Technology, United Airlines and Yext.
Published:
These five high-conviction health care picks make sense for accounts looking to gain exposure to a sector that should continue to do well the rest of 2020 and for years to come, given the aging...
Published:
With the potential for continued economic and political volatility, now is probably a good time for a little spring cleaning to portfolios. Here are six new additions to the Jefferies Franchise Picks...
Published:
These are five of the best stocks in a sector that has been humming along in what has been a turbulent year. They are all included on the Goldman Sachs Conviction List too.
Published:
Goldman Sachs analysts are bullish on these four top biotech stocks in front of first-quarter results. None of these companies is a proverbial one-trick pony, and they all are potential takeover...
Published:
Tuesday's top analyst calls included Advanced Micro Devices, Alcoa, Biomarin Pharmaceutical, Coca-Cola, Ford, General Motors, Intel, Kinder Morgan, Micron Technology, Nvidia, Tesla, Twitter and...
Published:
24/7 Wall St. has put together a preview of AbbVie, American Airlines, Netflix, Starbucks and some of the other most prominent earnings reports due in this truncated trading week.
Published:
These five top stocks spread across different sectors offer tremendous upside to the Goldman Sachs price objectives.
Published:
Tuesday's top analyst upgrades, downgrades and initiations included Albermarle, Amgen, Applied Materials, Biogen, CRISPR Therapeutics, CrowdStrike, CSX, Kroger, Slack, Teva Pharmaceutical and Xerox.
Published:
Wednesday's top analyst upgrades, downgrades and initiations included Advanced Micro Devices, Apple, Biomarin, Corning, Electronic Arts, FireEye, Grubhub, Nordstrom, NXP Semiconductors, Shopify and...
Published:
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Published:
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
Published:
The top analyst upgrades, downgrades and initiations on Wednesday included Acacia Communications, Baidu, BioMarin Pharmaceuticals, Boeing, BP, CSX, Deere, HCA, PepsiCo, Redfin, S&P Global,...
Published:
Last Updated: